The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Isocover     methyl(2S)-2-(2- chlorophenyl)-2-(7-thia-3...

Synonyms: Thrombo, Plavix, Zyllt, clopidogrel, Clopidogrelum, ...
 Bañuelos,  DeLago,  Pignatti,  Steinhubl,  Lewis,  Bass,  Peters,  Stranieri,  Harker,  Gustafson,  Monsma,  Mehta,  Armstrong,  Topol,  Cassar,  Macaya,  Chronos,  Fry,  Alfonso,  Zhai,  Fox,  Eisenberg,  Hankey,  Prosser,  Ellis,  Moses,  Culouscou,  Peters,  Wilmer,  Zachayus,  Smith,  Fernandez-Ortiz,  Leon,  Malmberg,  Westenfeld,  Porsche,  Pereillo,  Cowper,  Tripuraneni,  Bono,  Agans,  Eigenthaler,  Krämer,  Bonz,  Marzec,  Sokolova,  Teirstein,  Kelly,  Warlow,  Weitz,  Angiolillo,  Sketch,  Yusuf,  Bhatt,  Berger,  Sundell,  Nissen,  Copland,  Comerota,  Mehta,  Walter,  Kuntz,  Badimon,  Foster,  Lengenfelder,  Lira,  Herbert,  Natarajan,  Jimenez-Quevedo,  Alfonso,  Grossmann,  Uzabiaga,  Sabaté,  Liefeldt,  Cook,  Brittenden,  Abbondanzo,  Eriksson-Lepkowska,  Hanson, J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, C.S. Ernest, D.R. Lachno, D. Salazar, K.J. Winters,  Costa,  Zhang,  Fish,  Holmes,  Bachoo,  Wong,  Hirsh,  Bates,  Herbert,  Ford,  Moreno,  Daig,  Sarich,  Bylock,  Zhao,  Ferrara,  Bayne,  Mann,  Wiekowski,  Chrolavicius,  Sabaté,  Angiolillo,  Ramírez,  Elg,  Bernardo,  Delesque-Touchard,  Kerieakes,  Bernardo,  Hervé,  Bertrand,  Rupprecht,  Savi,  Hernández,  Greaves,  Nyström,  Khot,  Lachowicz,  Chintala,  Fernández,  Yusuf,  Gaedeke,  Jani,  Labouret,  Neumayer,  Wåhlander,  Escaned,  Obergfell,  Macaya,  Schnurr,  Peterson,  Kalies,  Fernandez-Ortiz,  Eriksson,  Lansky,  Trabetti,  Udayakumar,  
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of clopidogrel


Psychiatry related information on clopidogrel


High impact information on clopidogrel


Chemical compound and disease context of clopidogrel


Biological context of clopidogrel


Anatomical context of clopidogrel

  • Clopidogrel abolished cyclic flow variations in the coronary and femoral arteries of all five baboons (frequency of cyclic flow variations, 0/h versus 14/h at baseline, P < .001) [24].
  • In addition, we showed the predominant association of P2Y12 oligomers to cell membrane lipid rafts and the partitioning of P2Y12 out of rafts in response to clopidogrel and Act-Met [20].
  • Ex vivo inhibition of the P2Y12 ADP receptor by clopidogrel administration diminished the rapid exposure of tissue factor (TF), the major initiator of coagulation, in conjugates of platelets with leukocytes established by the contact of whole blood with fibrillar collagen [25].
  • Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [26].
  • The clopidogrel group had higher 24-h mean chest tube output (1,224 ml vs. 840 ml, p = 0.001), and more transfusions of red blood cells (2.51 U vs. 1.74 U, p = 0.036), platelets (0.86 U vs. 0.24 U, p = 0.001) and fresh frozen plasma (0.68 U vs. 0.24 U, p = 0.015) [27].

Associations of clopidogrel with other chemical compounds


Gene context of clopidogrel


Analytical, diagnostic and therapeutic context of clopidogrel


  1. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. Leon, M.B., Teirstein, P.S., Moses, J.W., Tripuraneni, P., Lansky, A.J., Jani, S., Wong, S.C., Fish, D., Ellis, S., Holmes, D.R., Kerieakes, D., Kuntz, R.E. N. Engl. J. Med. (2001) [Pubmed]
  2. Thrombotic thrombocytopenic purpura associated with clopidogrel. Bennett, C.L., Connors, J.M., Carwile, J.M., Moake, J.L., Bell, W.R., Tarantolo, S.R., McCarthy, L.J., Sarode, R., Hatfield, A.J., Feldman, M.D., Davidson, C.J., Tsai, H.M. N. Engl. J. Med. (2000) [Pubmed]
  3. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., Fox, K.K. N. Engl. J. Med. (2001) [Pubmed]
  4. Clopidogrel and membranous nephropathy. Tholl, U., Anlauf, M., Helmchen, U. Lancet (1999) [Pubmed]
  5. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. Mehta, S.R., Yusuf, S. J. Am. Coll. Cardiol. (2003) [Pubmed]
  6. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Bhatt, D.L., Bertrand, M.E., Berger, P.B., L'Allier, P.L., Moussa, I., Moses, J.W., Dangas, G., Taniuchi, M., Lasala, J.M., Holmes, D.R., Ellis, S.G., Topol, E.J. J. Am. Coll. Cardiol. (2002) [Pubmed]
  7. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Grossmann, R., Sokolova, O., Schnurr, A., Bonz, A., Porsche, C., Obergfell, A., Lengenfelder, B., Walter, U., Eigenthaler, M. Thromb. Haemost. (2004) [Pubmed]
  8. Variability in responsiveness to clopidogrel in patients with intermittent claudication. Cassar, K., Bachoo, P., Ford, I., Greaves, M., Brittenden, J. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. (2006) [Pubmed]
  9. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Sabaté, M., Fernández, C., Stranieri, C., Trabetti, E., Pignatti, P.F., Macaya, C. Blood Coagul. Fibrinolysis (2004) [Pubmed]
  10. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Hollopeter, G., Jantzen, H.M., Vincent, D., Li, G., England, L., Ramakrishnan, V., Yang, R.B., Nurden, P., Nurden, A., Julius, D., Conley, P.B. Nature (2001) [Pubmed]
  11. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Comerota, A.J. Atherosclerosis. Supplements. (2005) [Pubmed]
  12. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. Foster, C.J., Prosser, D.M., Agans, J.M., Zhai, Y., Smith, M.D., Lachowicz, J.E., Zhang, F.L., Gustafson, E., Monsma, F.J., Wiekowski, M.T., Abbondanzo, S.J., Cook, D.N., Bayne, M.L., Lira, S.A., Chintala, M.S. J. Clin. Invest. (2001) [Pubmed]
  13. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Mehta, S.R., Yusuf, S., Peters, R.J., Bertrand, M.E., Lewis, B.S., Natarajan, M.K., Malmberg, K., Rupprecht, H., Zhao, F., Chrolavicius, S., Copland, I., Fox, K.A. Lancet (2001) [Pubmed]
  14. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Hirsh, J., Bhatt, D.L. Arch. Intern. Med. (2004) [Pubmed]
  15. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. Dalby, M., Montalescot, G., Bal dit Sollier, C., Vicaut, E., Soulat, T., Collet, J.P., Choussat, R., Gallois, V., Drobinski, G., Drouet, L., Thomas, D. J. Am. Coll. Cardiol. (2004) [Pubmed]
  16. Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction. Weitz, J.I., Bates, S.M. Arch. Intern. Med. (2000) [Pubmed]
  17. Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. Lidell, C., Svedberg, L.E., Lindell, P., Bandh, S., Job, B., Wallentin, L. Thromb. Haemost. (2003) [Pubmed]
  18. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Wåhlander, K., Eriksson-Lepkowska, M., Nyström, P., Eriksson, U.G., Sarich, T.C., Badimon, J.J., Kalies, I., Elg, M., Bylock, A. Thromb. Haemost. (2006) [Pubmed]
  19. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Harker, L.A., Marzec, U.M., Kelly, A.B., Chronos, N.R., Sundell, I.B., Hanson, S.R., Herbert, J.M. Circulation (1998) [Pubmed]
  20. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Savi, P., Zachayus, J.L., Delesque-Touchard, N., Labouret, C., Hervé, C., Uzabiaga, M.F., Pereillo, J.M., Culouscou, J.M., Bono, F., Ferrara, P., Herbert, J.M. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  21. Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Sun, W., Gerhardinger, C., Dagher, Z., Hoehn, T., Lorenzi, M. Diabetes (2005) [Pubmed]
  22. Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. Khot, U.N., Nissen, S.E. J. Am. Coll. Cardiol. (2002) [Pubmed]
  23. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Geiger, J., Brich, J., Hönig-Liedl, P., Eigenthaler, M., Schanzenbächer, P., Herbert, J.M., Walter, U. Arterioscler. Thromb. Vasc. Biol. (1999) [Pubmed]
  24. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates. Yao, S.K., McNatt, J., Cui, K., Anderson, H.V., Maffrand, J.P., Buja, L.M., Willerson, J.T. Circulation (1993) [Pubmed]
  25. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Leon, C., Alex, M., Klocke, A., Morgenstern, E., Moosbauer, C., Eckly, A., Spannagl, M., Gachet, C., Engelmann, B. Blood (2004) [Pubmed]
  26. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Ramírez, C., Sabaté, M., Jimenez-Quevedo, P., Hernández, R., Moreno, R., Escaned, J., Alfonso, F., Bañuelos, C., Costa, M.A., Bass, T.A., Macaya, C. Diabetes (2005) [Pubmed]
  27. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. Hongo, R.H., Ley, J., Dick, S.E., Yee, R.R. J. Am. Coll. Cardiol. (2002) [Pubmed]
  28. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Hankey, G.J., Warlow, C.P. Lancet (1999) [Pubmed]
  29. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. Kamath, S., Blann, A.D., Chin, B.S., Lip, G.Y. J. Am. Coll. Cardiol. (2002) [Pubmed]
  30. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. Caro, J.J., Migliaccio-Walle, K. Am. J. Med. (1999) [Pubmed]
  31. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Armstrong, P.W. Eur. Heart J. (2006) [Pubmed]
  32. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. Sugidachi, A., Ogawa, T., Kurihara, A., Hagihara, K., Jakubowski, J.A., Hashimoto, M., Niitsu, Y., Asai, F. J. Thromb. Haemost. (2007) [Pubmed]
  33. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. Holinstat, M., Voss, B., Bilodeau, M.L., McLaughlin, J.N., Cleator, J., Hamm, H.E. J. Biol. Chem. (2006) [Pubmed]
  34. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis. Peters, H., Eisenberg, R., Daig, U., Liefeldt, L., Westenfeld, R., Gaedeke, J., Krämer, S., Neumayer, H.H. Kidney Int. (2004) [Pubmed]
  35. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. Richter, T., Mürdter, T.E., Heinkele, G., Pleiss, J., Tatzel, S., Schwab, M., Eichelbaum, M., Zanger, U.M. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  36. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Clarke, T.A., Waskell, L.A. Drug Metab. Dispos. (2003) [Pubmed]
  37. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. Aleil, B., Ravanat, C., Cazenave, J.P., Rochoux, G., Heitz, A., Gachet, C. J. Thromb. Haemost. (2005) [Pubmed]
  38. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Brandt, J.T., Close, S.L., Iturria, S.J., Payne, C.D., Farid, N.A., Ernest, C.S., Lachno, D.R., Salazar, D., Winters, K.J. J. Thromb. Haemost. (2007) [Pubmed]
  39. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Steinhubl, S.R., Berger, P.B., Mann, J.T., Fry, E.T., DeLago, A., Wilmer, C., Topol, E.J. JAMA (2002) [Pubmed]
  40. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. Cowper, P.A., Udayakumar, K., Sketch, M.H., Peterson, E.D. J. Am. Coll. Cardiol. (2005) [Pubmed]
  41. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. Xiao, Z., Théroux, P. J. Am. Coll. Cardiol. (2004) [Pubmed]
WikiGenes - Universities